Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management
Small · 2025
DOI: 10.1002/smll.202410345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, 2025. Verfasst von Sanoj Rejinold N und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, School of Science and Technology, Dankook University, Cheonan, 31116, Re…. Hauptthemen laut MEDLINE: Niclosamide, Nanotechnology. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Academy of Sciences, Republic of Korea.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has infected over 770 million people worldwide. The long‐term effects of COVID‐19 and their management have become important issues. Accumulating evidence indicates that post‐COVID‐19 syndrome, also known as long COVID, is not limited to respiratory symptoms but affects a wide range of systems, including neurological, cardiovascular, gastrointestinal, musculoskeletal, and reproductive systems etc. The social and economic losses associated with these effects are estimated to reach 3·7 trillion dollars in the United States alone. However, no treatment for long COVID has been developed. Herein, the literature on long COVID is comprehensively reviewed to examine the underlying causes. Additionally, evidence supporting the efficacy of nanoengineered niclosamide is presented, given its ability to counteract the underlying causes. Niclosamide is already Food and Drug Administration (FDA)‐approved, and the nanoengineered one is a viable candidate for clinical trials for long COVID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, School of Science and Technology, Dankook University, Cheonan, 31116, Republic of Korea.
- R&D Center, Hyundai Bioscience Co. LTD., Seoul, 07990, Republic of Korea.
- Division of Natural Sciences, The National Academy of Sciences, Seoul, 06579, Republic of Korea.
ORCID-Profile: Sanoj Rejinold N, Goeun Choi, Jin-Ho Choy
Förderung
- National Academy of Sciences, Republic of Korea
Zitieren
APA
Rejinold N, S., Choi, G., Jin, G. W., & Choy, J. H. (2025). Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management. Small. https://doi.org/10.1002/smll.202410345
Vancouver
Rejinold N S, Choi G, Jin GW, Choy JH. Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management. Small. 2025. doi:10.1002/smll.202410345
BibTeX
@article{RejinoldN2025,
author = {Rejinold N, Sanoj and Choi, Goeun and Jin, Geun-Woo and Choy, Jin-Ho},
title = {Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202410345}
}
EUVIMED